TPC RESEARCH HUB

This project examined the potential link between microplastic (MP) exposure and ADHD-related outcomes. Through a literature scan of peer-reviewed human and animal studies, findings suggested that MP exposure may contribute to hyperactivity, impulsivity, reduced working memory, and inattentiveness - outcomes relevant to ADHD. The research highlights microplastics as a potentially modifiable environmental contributor to ADHD and calls for further investigation in this emerging area. 

This research examined the quality of ADHD-related content across TikTok, Instagram, and YouTube, analyzing 200 posts to develop the Social Media Health Content Quality Scale (SMHCQS) - the first validated tool for assessing mental health content on social media. The study also produced an ADHD misinformation taxonomy to address common misconceptions. Findings provide practical tools for clinicians supporting patients whose understanding of ADHD is shaped by digital content, with both the scale and taxonomy freely available. 

Dr. Chavoshi and Dr. Riddell examined how environmental toxins - including lead, mercury, organophosphate pesticides, PCBs, PFAS, and fluoride - may contribute to ADHD risk. They discussed a 2018 study linking higher maternal urinary fluoride levels during pregnancy to increased ADHD symptoms in children aged 6–12 years, emphasizing the need to balance fluoride’s dental benefits with potential neurodevelopmental risks.

Their session called for stronger collaboration among clinicians, researchers, and policymakers to better understand and mitigate environmental contributors to ADHD.

Their review of 16 peer-reviewed studies (2000–2024) found that ADHD affects 16–26% of incarcerated adults, compared with roughly 4–5% in the general population. Despite this high prevalence, most facilities rely on informal observation rather than validated diagnostic tools.

Findings show that individuals with ADHD are 2.5 times more likely to receive institutional charges, account for eight times more aggressive incidents, and have a 38% six-month recidivism rate compared with 20% in non-ADHD groups. Pharmacological treatment, however, is associated with a 42% reduction in violent offenses, underscoring the impact of timely, evidence-based intervention.

The study calls for standardized ADHD screening at intake, consistent access to treatment, and continuity of care post-release to improve rehabilitation outcomes and reduce recidivism.

Psychedelic substances, particularly psilocybin and LSD, have attracted growing scientific interest for their potential effects on focus and cognition. Microdosing—taking sub-hallucinogenic doses—is increasingly self-reported by individuals with ADHD as a strategy to enhance productivity and attention, though evidence remains mixed and largely anecdotal.

Rigorous clinical trials are underway to clarify these effects. One example is a recently completed randomized, placebo-controlled phase 2 study (NCT05259943) examining the safety and efficacy of low-dose psilocybin. Participants completed attention and response inhibition assessments, including the Sustained Attention to Response Task (SART) and Metronome Response Task (MRT), following a structured dosing protocol over eight weeks.

As microdosing becomes more accessible and commercially promoted, robust research is essential—particularly for populations such as those with ADHD. To learn more about ongoing studies or to volunteer, visit psychedelicscience.ca.